Skip navigation
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBalakrishnan, Karthik-
dc.contributor.authorBartov, Eli-
dc.contributor.authorFaurel, Lucile-
dc.date.accessioned2008-11-13T16:25:42Z-
dc.date.available2008-11-13T16:25:42Z-
dc.date.issued2008-11-13T16:25:42Z-
dc.identifier.otherJEL classification: M41; G14.-
dc.identifier.urihttp://hdl.handle.net/2451/27762-
dc.description.abstractWe document a failure of the market to price the implications of a current loss (profit) for a future loss (profit). In a 120-day window following the quarterly earnings announcement date, a portfolio of firms with extreme losses (profits) exhibits a -6.58 percent (3.55 percent) abnormal return. These patterns in stock returns translate into an annualized return of approximately 21 percent on a hedge portfolio that takes a long position in an extreme profit firm quintile and a short position in an extreme loss firm quintile. The results also demonstrate that this loss/profit anomaly is incremental to, and more pronounced than previously documented accounting-related anomalies. In an effort to explain this finding, we show that this mispricing is related to differences between conditional and unconditional probabilities of losses/profits, as if stock prices do not fully reflect conditional probabilities in a timely fashion. A battery of sensitivity tests shows that this loss/profit anomaly is robust to alternative risk adjustments, distress risk, short sales constraints, transaction costs, and sample periods.en
dc.format.extent508734 bytes-
dc.format.mimetypeapplication/pdf-
dc.language.isoen_USen
dc.subjectLoss/profit mispricing;en
dc.subjectloss/profit predictability;en
dc.subjectaccounting losses;en
dc.subjectaccounting profits;en
dc.subjectearnings-based anomaliesen
dc.titlePost Loss/Profit Announcement Driften
dc.typeWorking Paperen
Appears in Collections:Accounting Working Papers

Files in This Item:
File Description SizeFormat 
Post Losses Announcement Drift 10-2008.pdf496.81 kBAdobe PDFView/Open


Items in FDA are protected by copyright, with all rights reserved, unless otherwise indicated.